Neurologic medications

Neuro medication items are toxicity clocks: phenytoin levels, on-time myasthenia pills, and knowing when a migraine drug is unsafe for the heart.

Antiepileptics

Phenytoin narrows the gap between “controlled” and “toxic.” When serum levels climb, cerebellar and vestibular circuits misfire - that is why nystagmus, ataxia, diplopia, and slurred speech show up before a dramatic seizure story. A high level plus those signs is not a “wait for the next dose” moment: hold the drug, keep the client safe while unsteady, and notify so the plan can adjust.

IV phenytoin is a compatibility and rate problem as much as a dose problem. Classic teaching mixes it with normal saline only - dextrose makes it precipitate - and runs it slowly with cardiac monitoring because rapid infusion can depress the heart. Facility protocols own the exact rate; the exam trap is hanging it in D5W or racing it in. Chronic oral use also thickens gingival tissue, so brush/floss teaching is not cosmetic - it prevents the hyperplasia from becoming a bleeding, infection-prone mouth. Stopping suddenly removes seizure control; taper only with a provider plan.

Other antiepileptics carry their own watch list. Valproic acid / divalproex: hepatotoxicity and pancreatitis cues (severe abdominal pain, vomiting, jaundice), tremor, and strong teratogenicity teaching - pregnancy planning matters. Carbamazepine: dizziness, blood dyscrasias, and serious rash - report fever, sore throat, bruising, or blistering skin. Benzodiazepines and barbiturates sedate and can depress respiration; they appear in acute seizure pathways and as adjuncts. Across the class, abrupt stop can provoke seizures - hold for toxicity with a provider plan, not a silent home quit.

Distractor logic: giving another dose “because the level is high” worsens toxicity; flushing the IV with dextrose risks a crystal line; skipping dental teaching ignores a predictable chronic effect. Edge case - ataxia with a high level is a fall and aspiration risk even before you sort the lab paperwork.

Parkinson and migraine drugs

Levodopa is a dopamine precursor; carbidopa blocks peripheral breakdown so more reaches the brain. That partnership improves motor symptoms, but the timing around meals and the expected oddities matter as much as the pill itself. High-protein meals can compete with levodopa absorption for some clients - teach consistent timing relative to meals as ordered, not random snacking around doses. Dark urine or sweat is a known pigment change, not bleeding. What you escalate is loss of effect (“off” periods), severe dyskinesia, or hallucinations - those mean the dose–response window has shifted. Orthostatic hypotension and fall risk travel with many Parkinson regimens; rise slowly.

• Levodopa/carbidopa: expected dark body fluids; take consistently relative to meals as taught.
• Report hallucinations, severe dyskinesia, or sudden “off” periods per plan.
• Do not abruptly stop dopaminergic therapy without a plan - rigidity and fever patterns can worsen.

Triptans such as sumatriptan abort migraine by constricting cranial vessels. The same vasoconstriction is why a client with significant CAD or uncontrolled hypertension is the wrong candidate - coronary arteries can tighten too. Chest-pain history on the medication list is a stop-and-clarify cue, not a “give and watch” cue. Ergot-type agents share vasoconstriction concerns. Preventive migraine drugs (beta-blockers, certain antiepileptics as tested) are a different daily plan - do not confuse abortive timing with prevention.

Distractor on Parkinson items: treating expected dark urine as a hemorrhage workup while missing an “off” period that needs the timed dose. Distractor on migraine items: giving a triptan for pain when the cardiac history already contraindicates it - comfort measures and clarifying with the provider beat a vasoconstrictor in a diseased coronary tree.

Donepezil and related Alzheimer cholinesterase inhibitors raise acetylcholine in remaining synapses. Families need honest teaching: the drug may slow decline for a while; it does not restore lost memory. Watch for nausea, diarrhea, insomnia, and bradycardia or syncope. Evening dosing is common when the label says so; follow the order in front of you. The distractor is promising a cure or ignoring new syncope as “just aging.”

Myasthenia and cholinesterase inhibitors

Myasthenia gravis leaves too little acetylcholine effect at the neuromuscular junction. Cholinesterase inhibitors such as pyridostigmine slow ACh breakdown so strength returns - but only while the drug is in the system. That is why these are clock drugs: a late dose means weak swallow, weak lids, and weak respiratory muscles before the next pill can catch up.

Both myasthenic crisis (not enough drug effect) and cholinergic crisis (too much drug) can look like weakness. The fork is the muscarinic picture: salivation, lacrimation, diarrhea, bradycardia, and other SLUDGE/DUMBBELS signs point to cholinergic excess - more cholinesterase inhibitor then makes things worse. Hold the drug, protect the airway, and follow the atropine pathway as ordered. When the stem shows a late dose without cholinergic signs, the bedside move is safety for swallow/airway and getting the schedule back on track with the team - not assuming atropine first.

1. Give cholinesterase inhibitors on schedule - strength depends on it.
2. Differentiate myasthenic weakness (needs more effect) from cholinergic crisis (too much drug) with the provider’s testing/plan.
3. Cholinergic excess: hold med, airway support, atropine as ordered.

Exam trap: giving another pyridostigmine dose into a drooling, bradycardic client. Edge case: weak swallow after a missed dose is an airway and aspiration problem while you restore the schedule - do not leave the client eating unsupervised just because “the pill is due soon.”

Priority map